JG
ALDX icon

Jefferies Group’s Aldeyra Therapeutics ALDX Stock Holding History

Jefferies Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-59,200
Closed -$237K – 1507
2021
Q4 		$237K Buy
+59,200
New +$452K ﹤0.01% 1357

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Jefferies Group's ALDX Position: Q3 2022 in Review

Jefferies Group opened a new position in Aldeyra Therapeutics (ALDX) in Q3 2022: 807 shares worth $4.31K. The stake represents ﹤0.01% of the portfolio and ranks #1573 among its holdings. This is a return to the name: Jefferies Group previously reported a position in ALDX as recently as Q2 2021.

Jefferies Group first reported a position in ALDX in Q1 2018 and has held it in 5 quarters since. The position peaked at $680K in Q2 2021. 89 funds tracked by Wall St. Rank hold ALDX as of Q3 2022.

  • Jefferies Group held 807 shares of Aldeyra Therapeutics worth $4.31K as of Q3 2022.
  • Aldeyra Therapeutics was a new Jefferies Group position in Q3 2022.
  • Aldeyra Therapeutics made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1573 holding.
  • Jefferies Group first reported a position in Aldeyra Therapeutics in Q1 2018 and has held it in 5 quarters since.
  • Jefferies Group's Aldeyra Therapeutics position peaked at $680K in Q2 2021.
  • 89 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.